Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trisenox Plus Thalomid in Myelodysplastic Syndrome
NCT00251511Phase 2Terminated
- Sponsor
- Veeda Lifesciences
- Start
- Aug 2004
- Primary completion
- Jan 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and thalidomide in myelodysplastic syndrome (MDS), sponsored by Veeda Lifesciences. Primary endpoint: Objective Response Rate. Started Aug 2004; status: terminated.
02
Drugs
arsenic trioxidethalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00251511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251511.